论文部分内容阅读
Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma(PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients(80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are des-perately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC.
Despite the lack of early diagnostic tools due to the lack of early diagnostic tools due to lack of early diagnostic tools and reliable therapeutic approaches. A majority of patients (80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. we will highlight the translational studies demonstrations that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC.